GLP-1 Chart

Mounjaro vs Zepbound

Mounjaro vs Zepbound: both brands hold the same medicine, tirzepatide, from the same maker, Eli Lilly.

Prefer

Last updated October 18, 2026. Labels read October 6, 2026.

Learn

More about this page

Tirzepatide acts on two hormone receptors, GIP and GLP-1. GLP-1 is a hormone from the gut that helps the body manage blood sugar and eating. The two brands have separate FDA labels with different approved uses. Both labels were updated in late August 2026.

Source: Drucker DJ, Cell Metabolism 2018, PMID 29617641.

The two labels side by side

Label factMounjaroZepbound
Medicine (molecule)tirzepatidetirzepatide
TypeGIP and GLP-1
MOUNJARO® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
GIP and GLP-1
ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
Maker on the labelEli Lilly and CompanyEli Lilly and Company
Taken asInjection: pen or vial pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPensInjection: pen or vial pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens
How often, per labelOnce weekly Administer MOUNJARO once weekly, any time of day, with or without meals.Once weekly Administer ZEPBOUND once weekly at any time of day, with or without meals.
Approved uses, per label
  • Blood sugar in type 2 diabetes as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
  • Lower risk of major cardiovascular events to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events
  • Excess body weight, long term to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition
  • Obstructive sleep apnea to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity
Boxed warningYes WARNING: RISK OF THYROID C-CELL TUMORSYes WARNING: RISK OF THYROID C-CELL TUMORS
Label readMounjaro label, version 40, effective August 27, 2026Zepbound label, version 40, effective August 28, 2026
FDA approval recordNDA215866, first approved May 13, 2022NDA217806, first approved November 8, 2023

Each cell is the label's own wording, and each label link opens the exact DailyMed version we read.

What the two labels share

  • The medicine. Tirzepatide is the medicine on both. Both describe it as a GIP receptor and GLP-1 receptor agonist.
  • The maker. Both labels name Eli Lilly and Company.
  • The form. Both list pens and vials for a shot under the skin, once weekly.
  • The boxed warning. A boxed warning on thyroid C-cell tumors sits at the top of each label.

Where the two labels differ

  • Approved uses. The Mounjaro label is about type 2 diabetes. It lists blood sugar control and, for adults with type 2 diabetes at high risk, a lower risk of major cardiovascular events. The label defines those as cardiovascular death, a heart attack that is not fatal, or a stroke that is not fatal. The Zepbound label lists excess body weight and obstructive sleep apnea in adults with obesity.
  • Ages. The Mounjaro label includes children 10 years and older for blood sugar control. The Zepbound label lists adults.
  • FDA approval records. Mounjaro was first approved in 2022 and Zepbound in 2023, under separate applications.

Using tirzepatide products together

The Zepbound label has a limitation of use about other tirzepatide products and GLP-1 medicines. The label's exact words are below.

Zepbound label, section 1, Limitations of UseCoadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

More side by side pages

For the two semaglutide brands, see Ozempic vs Wegovy. For tirzepatide next to semaglutide, see tirzepatide vs semaglutide. The how do GLP-1 drugs work page explains how each one acts. To compare any other pair, use the GLP-1 comparison chart.

Questions

Is Mounjaro the same as Zepbound?

Mounjaro and Zepbound hold the same medicine, tirzepatide, from the same maker. But each has its own FDA label, with its own approved uses.

What is the difference between Mounjaro and Zepbound?

The labels differ in approved uses and ages. Mounjaro's label is for type 2 diabetes, including children 10 and older for blood sugar. Zepbound's label is for excess body weight and sleep apnea in adults.

Is Mounjaro a GLP-1?

Mounjaro acts on GLP-1 and on a second hormone receptor. The Mounjaro label calls tirzepatide a GIP receptor and GLP-1 receptor agonist.

Is Zepbound a GLP-1?

The Zepbound label uses the same words as Mounjaro: a GIP receptor and GLP-1 receptor agonist. So it acts on GLP-1 and on GIP.

Sources

4 sources with read dates
  1. Mounjaro label on DailyMed, Eli Lilly, version 40 of 2026-08-27, read 2026-10-06
  2. Zepbound label on DailyMed, Eli Lilly, version 40 of 2026-08-28, read 2026-10-06
  3. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06
  4. Drugs@FDA application records for NDA 215866 and 217806, US Food and Drug Administration, via the openFDA drugsfda API, read 2026-10-06